In Brief: Commissioner Kessler's last day
Executive Summary
Commissioner Kessler's last day: Departed FDA commissioner participated in a White House ceremony marking the beginning of the first phase of FDA tobacco regulations on Feb. 28, Kessler's last day with the agency. Kessler becomes dean of Yale Medical School July 1 ("The Pink Sheet" Feb. 17, In Brief). At a Feb. 28 session of the Cosmetic, Toiletry & Fragrance Association's annual meeting, association President Edward Kavanaugh, introduced CTFA outside counsel Peter Barton Hutt (Covington & Burling) by feeding speculation that Hutt is a candidate to succeed Kessler. "Rumors around the last week or so have you in the final three candidates," Kavanaugh said...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth